The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•13 February 2026•

1 min read

INNOVATE Corp's MediBeacon Technology Recognized by American Society of Nephrology

INNOVATE Corp (VATE) announced that its subsidiary, MediBeacon, has received significant academic recognition for its kidney function monitoring technology. The Journal of the American Society of Nephrology (JASN) selected an article on MediBeacon’s transdermal glomerular filtration rate (tGFR) technology as a 2025 Editors’ Choice. This recognition highlights the clinical importance of the TGFR System, which is currently being deployed across several clinical centers of excellence. The technology aims to provide a more accurate and efficient method for measuring kidney function compared to traditional methods. By securing this endorsement, MediBeacon seeks to establish its proprietary system as a new global standard of care in nephrology. This development validates the commercial potential of INNOVATE Corp’s life sciences portfolio, potentially driving long-term value for shareholders.

Sources: